A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
A phase 1/2 trial of Abiraterone acetate, Prednisone in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
Overview
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT05067140 by Novartis Pharmaceuticals, with 164 participants enrolled, started 2021-09-02 and due to reach its primary completion in 2027-05-25. Interventions recorded: ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone), Androgen Deprivation Therapy (ADT). Conditions listed: Prostate Cancer Metastatic. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Ver
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc
Shares Abiraterone acetate, Novartis, Prostate cancer.
- TrialTulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in
Shares Abiraterone acetate, Novartis, Prostate cancer.
- TrialA Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialAn Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer
Shares Prednisone, Abiraterone acetate, Prostate cancer.